TOTOWA, N.J., July 9, 2014 /PRNewswire/ — BiologicTx today announced the acquisition of Injectable Therapy Services, Inc., in Los Angeles, California, near the UCLA Campus. Injectable Therapy Services (ITS) provides solid organ transplant and other specialty pharmacy services nationally, including biologic, oral, and outpatient therapies through their Infusion Center and in the patient’s home.

“We are committed to expanding our advanced pharmacy, research and digital health services through an aggressive growth strategy on a national level,” said Darrin Carrico, President and Co-founder of BiologicTx. “The acquisition of ITS serves as a hub site for clinical research and will increase reachability to our patients.”

About BiologicTx
BiologicTx is a national specialty pharmacy that joins the administration of therapeutics, research, and digital health to advance the practice of solid organ transplant and chronic specialties. BiologicTx is comprised of four operating segments: BiologicTx Pharmacy and Therapeutic Services; BiologicTx Clinical Trials™, which designs, sponsors, and aggregates clinical data, assisting in the publication of multicenter studies; BiologicTx Sequence™, a digital health platform, including clinical intelligence and data integration, supporting clinicians and patients in achieving optimal outcomes; and BiologicTx Paired Donation™, which offers an advanced software matching system, MatchGrid, and clinical decision intelligence to transplant centers. For more information, visit us at: www.BiologicTx.com.

Logo – http://photos.prnewswire.com/prnh/20130520/LA16505LOGO

SOURCE BiologicTx